Engerix-B may be given subcutaneously to persons at risk of hemorrhage (eg, hemophiliacs). However, hepatitis B vaccines given subcutaneously are known to result in a lower antibody response.

Adults typically receive the hepatitis B vaccine in a two- or three-dose series. Engerix-B is also offered as a four-dose series for adults who are undergoing hemodialysis (kidney dialysis).

Such protection was seen in only 80.6% of subjects who received hepatitis B vaccine with an aluminum hydroxide adjuvant, known as HepB-alum, (trade name Engerix-B). "These results suggest a ...

Trials with Heplisav were halted last month in response to a serious adverse effect report from a phase 3 trial comparing Heplisav to a marketed hepatitis B vaccine, Engerix-B, sold by ...

Dynavax should take a leaf from its vaccine maker peer ... concern that the FDA was protecting GlaxoSmithKline's Engerix-B Hep B franchise. No longer. After several years of effort and expense ...

Cumulative exposure for 7 days Manufacturer Hepatitis B vaccine (recombinant) Engerix-B (GlaxoSmithKline) 72 hr Manufacturer Immune globulin (human) Gamastan S/D (Bayer) Cumulative exposure for 7 ...